{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T12:39:23Z","timestamp":1778762363557,"version":"3.51.4"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.yebeh.2020.107515","type":"journal-article","created":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T00:37:19Z","timestamp":1613608639000},"page":"107515","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Positive and negative effects of perampanel treatment on psychiatric and behavioral symptoms in adult patients with epilepsy"],"prefix":"10.1016","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8304-9218","authenticated-orcid":false,"given":"Naoya","family":"Hasegawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6468-901X","authenticated-orcid":false,"given":"Jun","family":"Tohyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2020.107515_bb0005","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.yebeh.2016.06.040","article-title":"Psychiatric comorbidities in epilepsy: should they be considered in the classification of epileptic disorders?","volume":"64","author":"Kanner","year":"2016","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2020.107515_bb0010","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1212\/01.WNL.0000103282.62353.85","article-title":"Depression but not seizure frequency predicts quality of life in treatment-resistant epilepsy","volume":"62","author":"Boylan","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2020.107515_bb0015","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/S0140-6736(13)60899-5","article-title":"Premature mortality in epilepsy and the role of psychiatric comorbidity: a total population study","volume":"382","author":"Fazel","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.yebeh.2020.107515_bb0020","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1155\/2011\/450635","article-title":"Ictal and peri-ictal psychopathology","volume":"24","author":"Mula","year":"2011","journal-title":"Behav Neurol"},{"key":"10.1016\/j.yebeh.2020.107515_bb0025","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.braindev.2017.01.006","article-title":"Cognitive and behavioral effects of new antiepileptic drugs in pediatric epilepsy","volume":"39","author":"Moavero","year":"2017","journal-title":"Brain Dev"},{"key":"10.1016\/j.yebeh.2020.107515_bb0030","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.yebeh.2017.08.039","article-title":"Psychiatric and behavioral side effects of antiepileptic drugs in adults with epilepsy","volume":"76","author":"Chen","year":"2017","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2020.107515_bb0035","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/ane.12100","article-title":"Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonist","author":"Rogawski","year":"2013","journal-title":"Acta Neurol Scand Suppl"},{"key":"10.1016\/j.yebeh.2020.107515_bb0040","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1528-1167.2012.03648.x","article-title":"Perampanel, a selective, noncompetitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, extension study 307","volume":"54","author":"Krauss","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2020.107515_bb0045","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1111\/epi.12212","article-title":"Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies","volume":"54","author":"Steinhoff","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2020.107515_bb0050","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/2064027","article-title":"Mechanisms underlying aggressive behavior induced by antiepileptic drugs: focus on topiramate, levetiracetam, and perampanel","volume":"2018","author":"Hansen","year":"2018","journal-title":"Behav Neurol"},{"issue":"Suppl. 1","key":"10.1016\/j.yebeh.2020.107515_bb0055","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/epi.12504","article-title":"Adverse effects and safety profile of perampanel: a review of pooled data","volume":"55","author":"Rugg-Gunn","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2020.107515_bb0060","series-title":"Diagnostic and statistical manual of mental disorders (DSM-5\u00ae)","author":"Association AP","year":"2013"},{"key":"10.1016\/j.yebeh.2020.107515_bb0065","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1111\/epi.13054","article-title":"Psychiatric and behavioral adverse events in randomized clinical studies of the noncompetitive AMPA receptor antagonist perampanel","volume":"56","author":"Ettinger","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2020.107515_bb0070","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1212\/WNL.0000000000001930","article-title":"Perampanel for tonic\u2013clonic seizures in idiopathic generalized epilepsy a randomized trial","volume":"85","author":"French","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2020.107515_bb0075","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1111\/epi.12643","article-title":"Long-term safety of perampanel and seizure outcomes in refractory partial-onset seizures and secondarily generalized seizures: results from phase III extension study 307","volume":"55","author":"Krauss","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2020.107515_bb0080","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/s41398-019-0624-1","article-title":"Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites","volume":"9","author":"Yang","year":"2019","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.yebeh.2020.107515_bb0085","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.brainres.2015.01.001","article-title":"Differential role of AMPA receptors in mouse tests of antidepressant and anxiolytic action","volume":"1601","author":"Andreasen","year":"2015","journal-title":"Brain Res"},{"key":"10.1016\/j.yebeh.2020.107515_bb0090","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1124\/pr.115.012021","article-title":"Epilepsy, antiepileptic drugs, and aggression: an evidence-based review","volume":"68","author":"Brodie","year":"2016","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.yebeh.2020.107515_bb0095","article-title":"Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users","volume":"3","author":"Baandrup","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.yebeh.2020.107515_bb0100","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1111\/j.1528-1167.2009.02424.x","article-title":"Interictal dysphoric disorder and periictal dysphoric symptoms in patients with epilepsy","volume":"51","author":"Mula","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2020.107515_bb0105","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s11920-019-1029-9","article-title":"The relationship between epilepsy and anxiety disorders","volume":"21","author":"Hingray","year":"2019","journal-title":"Curr Psychiatry Rep"},{"key":"10.1016\/j.yebeh.2020.107515_bb0110","doi-asserted-by":"crossref","first-page":"939","DOI":"10.3389\/fneur.2019.00939","article-title":"Transient epileptic amnesia: a treatable cause of spells associated with persistent cognitive symptoms","volume":"10","author":"Ramanan","year":"2019","journal-title":"Front Neurol"},{"key":"10.1016\/j.yebeh.2020.107515_bb0115","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/ana.21111","article-title":"The syndrome of transient epileptic amnesia","volume":"61","author":"Butler","year":"2007","journal-title":"Ann Neurol"},{"key":"10.1016\/j.yebeh.2020.107515_bb0120","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.seizure.2020.01.021","article-title":"Perampanel effect on sleep architecture in patients with epilepsy","volume":"76","author":"Rocamora","year":"2020","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2020.107515_bb0125","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.yebeh.2016.08.004","article-title":"Sleep quality and daytime sleepiness in patients treated with adjunctive perampanel for focal seizures","volume":"63","author":"Toledo","year":"2016","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2020.107515_bb0130","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/epi.12865","article-title":"The clinical pharmacology profile of the new antiepileptic drug perampanel: a novel noncompetitive AMPA receptor antagonist","volume":"56","author":"Patsalos","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2020.107515_bb0135","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19072143","article-title":"A history of the pharmacological treatment of bipolar disorder","volume":"19","author":"Lopez-Munoz","year":"2018","journal-title":"Int J Mol Sci"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505020306958?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505020306958?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:41:29Z","timestamp":1761504089000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505020306958"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":27,"alternative-id":["S1525505020306958"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2020.107515","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Positive and negative effects of perampanel treatment on psychiatric and behavioral symptoms in adult patients with epilepsy","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2020.107515","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107515"}}